Hypertension in Acromegaly in Relationship to Biochemical Control and Mortality: Global ACROSTUDY Outcomes by Vila, G. (Greisa) et al.
Frontiers in Endocrinology | www.frontiersi
Edited by:
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Context: Hypertension is a major cardiovascular risk factor related to increased mortality
in acromegaly. Surgical cure of acromegaly is associated with improvement in blood
pressure levels, however little is known about the effect of pegvisomant (PEGV) treatment
in patients with hypertension. This analysis evaluates outcomes in patients with
hypertension and acromegaly included in ACROSTUDY.
Methods: ACROSTUDY is a global non-interventional surveillance study of long-term
treatment with PEGV, monitoring its safety and efficacy. The cohort was retrospectively
divided in two subgroups: patients with and without hypertension. Stepwise logistic
regression and Kaplan-Meyer analyses were performed for testing predictors of mortality.
Results: The total cohort included 2,090 patients with acromegaly treated with PEGV
who were followed for a median of 6.8 years (range up to 12.1 years). In ACROSTUDY
there were 1,344 patients with hypertension (52.3%males). This subgroup was older, had
a higher BMI, and higher prevalence of diabetes, hyperlipidemia, and cardiovascular
disease (CVD) when compared to patients without hypertension. During ACROSTUDY,
68 deaths were reported in the hypertension cohort, vs 10 in the cohort without
hypertension. Both CVD (p<0.0001) and anterior pituitary deficiencies (p=0.0105) at
study entry independently predicted mortality in patients with acromegaly and
hypertension; Kaplan-Meier analysis confirmed that CVD significantly impairs survival.
Conclusions: Hypertension is common in patients with acromegaly and significantly
increases mortality, especially when there is concomitant CVD. These data suggest that
treatment goals should extend beyond IGF-I normalization, and include optimisation of
substitution of pituitary deficiencies and scrutinous screening and treatment of CVD.
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Hypertension is a classical cardiovascular risk factor and the
most prevalent cardiovascular comorbidity accompanying
acromegaly, reported in 15–60% of registry based acromegaly
cohorts (1–7). The severity of hypertension in acromegaly is
related to GH-IGF-I excess, which is associated with enhanced
sodium- and water retention, expansion of plasma volume and
increased systemic vascular resistance (8–10).
Both GH hypersecretion and hypertension contribute to the
pathophysiology of cardiovascular changes accompanying
acromegaly, which include left ventricular hypertrophy,
cardiomyopathy, valvular disease, arrhythmias, and heart
failure (5, 8). GH hypersecretion is considered the most
important causitive factor, as it has a strong impact on heart
morphology and function, independent of blood pressure (5, 11,
12). Several studies reported that hypertension plays an additive
role aggravating the cardiomyopathy and increasing
cardiovascular risk in acromegaly (5, 13). Although cardiac
disease is highly prevalent in patients with acromegaly, with
over 70% of cases in autopsy studies, and has even been found in
asymptomatic patients, several studies have shown that
acromegaly per se is not specifically associated with an
increased incidence of coronary heart disease (10, 11, 14).
Nevertheless, the atherogenic effects of most acromegaly
comorbidities such as hypertension, insulin resistance, diabetes,
hyperlipidemia and sleep apnea, as well as the acromegaly
cardiomyopathy, all contribute to the increased incidence of
cardiovascular and cerebrovascular diseases in this population
(8, 10, 15).
Acromegaly is also associated with an excess in mortality,
predominantly due to cardiovascular and cerebrovascular
diseases, and several studies have confirmed that normalisation
in GH/IGF-I ameliorates and even nearly normalizes mortality
rate (16–18). Mortality in patients with acromegaly is directly
associated to IGF-I concentrations, older age, the presence of
hypertension and duration of symptoms prior to diagnosis (13,
19). Therefore, the optimal management of acromegaly includes
the normalisation of GH/IGF-I levels and disease symptoms, as
well as the evaluation and treatment of comorbidities, aiming at
reducing morbidity and mortality (20, 21).
Here we prospectively studied patients with acromegaly
included in ACROSTUDY™ receiving pegvisomant, aiming at
characterising the cohort of patients with hypertension, their
biochemical control, comorbidities, and factors related
to mortality.PATIENTS AND METHODS
Study Protocol
ACROSTUDY™ is a global non-interventional surveillance
study of long-term treatment with pegvisomant established in
2004 for evaluating outcomes in patients with acromegaly (22,
23). The study prospectively recruited patients in 204 centers
from 15 countries and adhered to all applicable local laws andFrontiers in Endocrinology | www.frontiersin.org 2regulatory requirements; local ethical approval was obtained for
each participating center and all patients were enrolled after
providing written informed consent. Patients were eligible for
inclusion if they were on PEGV treatment, or if they were about
to start PEGV therapy. Exclusion criteria were participation in
any interventional trial and/or tumor mass problems requiring
surgical decompression. Study protocol details have been
described in previous publications (4, 22, 23). Importantly,
decisions on acromegaly treatment were made by the
investigators following the routine clinical practice of specific
clinics and countries.
Follow-up visits were scheduled following the practice of the
treating physician, generally at least once yearly. Case report
forms were specially designed for capturing comorbidities and
cardiovascular risk factors in addition to acromegaly-specific
outcomes, and the following parameters were obtained at
baseline (entry in the ACROSTUDY) and during each follow-
up visit: blood pressure, weight, height, GH, IGF-I, liver function
tests, plasma glucose, HbA1c, comorbidities, current medication
(including any changes and reasons for changing), and
information on pituitary imaging. At baseline and at each visit,
the investigators were asked to confirm the presence or absence
of the following cardiovascular risk factors: hypertension,
smoking, obesity, diabetes, hyperlipidemia, as well as the
presence of cardiovascular and cerebrovascular diseases.
Mortality
For the present study, we evaluated data from the 2nd interim
analysis database freeze on the 12th of May 2016, which included
2090 patients followed up for a median of 6.8 years with a
maximum of 12.1 years (23). Data on mortality during the study
period were obtained from the adverse report forms, which were
evaluated by two independent researchers for verifying the cause
of death given by the investigator.
Hypertension Group
For this analysis, patients were retrospectively divided in two
cohorts: Hypertension and Normotension. Patients were
included in the Hypertension group if they were identified to
have hypertension at any visit during the ACROSTUDY. The
presence of hypertension was determined when at least one of
the following three was present: 1) hypertension listed as
comorbidity by the investigator, 2) antihypertensive
medication was used and 3) systolic blood pressure was
>140 mm Hg and/or diastolic blood pressure was >90 mm Hg.
Comorbidities
The presence of comorbidities at ACROSTUDY entry was
evaluated by asking the investigators to fill in the study report
form with “yes” or “no” for the presence of diabetes,
hyperlipidemia, coronary heart disease, coronary angioplasty
with or without stent implantation, coronary artery bypass
surgery, arrhythmia, heart failure, myocardial infarction,
transient ischemic attack, cerebrovascular event, sleep apnea,
other respiratory disease, liver disease, gallstones, and cancer.
Diabetes was diagnosed if at least one of the following was
present: 1) diabetes given as a comorbidity by the investigator, 2)November 2020 | Volume 11 | Article 577173
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≥6.5% (48 mmol/mol), or random glucose >200 mg/dl (11.1
mmol/L) as previously described (24). Hyperlipidemia was
diagnosed if at least one of the following was present: 1)
hyperlipidemia given as comorbidity by the investigator, 2)
concomitant intake of lipid-lowering drugs.
Patients were considered to have cardiovascular disease (CVD)
at baseline if any of the following was reported at ACROSTUDY
entry: left ventricular hypertrophy, cardiomyopathy, aortic valvular
disorders, mitral valvular disorders, tricuspid valvular disorders,
arrhythmias, myocardial ischaemia, myocardial infarction, heart
failure, cerebrovascular accident, transient ischaemic attack,
haemorrhagic stroke and ischaemic stroke.
Statistical Analysis
Continuous measurements were summarized using descriptive
statistics and discrete data by counts. Demographic and co-
morbidities of acromegaly patients enrolled in the study are
summarized descriptively by hypertensive and normotensive
groups. As this is a non-interventional study, all tests of
significance provided (eg., p-values) are exploratory, not
definitive and post-hoc in nature and should be interpreted
with caution. Stepwise logistic regression for mortality was
performed using independent predictors of demographic,
clinical and co-morbid risk factors. Odds ratios and 95%
confidence intervals for them are also provided. Kaplan-Meier
analyses were performed for the significant predictors of
mortality and survival from the stepwise logistic regression
analysis for the total cohort of patients and within the
hypertensive sub-cohort.
For the purposes of statistical analyses, baseline was defined
as the start of PEGV therapy upon entry in the ACROSTUDY.
For adverse event (AE) reporting, including serious adverse
events (SAEs), death and laboratory results, safety data wereFrontiers in Endocrinology | www.frontiersin.org 3assessed at all visits through case report forms and spontaneous
reports. Adverse events data were coded using the current
MedDRA version available at the time of reporting. All
statistical analyses are performed using SAS version 9.4 (25).RESULTS
Here we analyse data from 2,090 patients followed for a median
of 6.8 years (range up to 12.1 yrs), in total, 7,687.5 patient years
(Figure 1). Data on acromegaly treatment outcomes were
already reported previously (23).
Characteristics of the
Hypertension Cohort
The prevalence of hypertension in the ACROSTUDY cohort was
56% at study entry and increased to 64% during the follow-up
period, with 182 newly diagnosed patients with hypertension
during the study (Figure 1). For this analysis, the entire
ACROSTUDY population was divided in two groups: 1)
patients with hypertension at any time during the study (64%
of patients) and 2) patients with normotension at any time
during the study (36% of patients). Baseline demographic
characteristics of the cohorts with and without hypertension
are shown in Table 1. At study entry, patients belonging to the
hypertension group were older at initial diagnosis of acromegaly,
older at study entry, had higher BMI and a higher prevalence of
all cardiovascular risk factors (Table 1). In addition, patients
with hypertension had significantly more pituitary deficiencies
and received less pituitary surgery (Table 1). Patients who
started PEGV ≥5 years after diagnosis had a higher prevalence
of hypertension. At baseline and at year 5, the average blood
pressure reduced from 137/84 to 134/81 mmHg in Hypertension
and 122/76 to 120/75 mmHg in Normotension groups,FIGURE 1 | ACROSTUDY flow chart.November 2020 | Volume 11 | Article 577173
Vila et al. Hypertension in Acromegalyrespectively. 20.4% of patients receiving PEGV monotherapy,
19.7% of patients receiving PEGV + somatostatin receptor
ligands (SRL), 20.7% of patients receiving PEGV + dopamine
agonists (DA) and 24.1% of patients receiving tripple therapy
(PEGV + SRL + DA) developed novel hypertension during the
observation time in ACROSTUDY.Frontiers in Endocrinology | www.frontiersin.org 4Acromegaly Control Rates in the
Hypertension Cohort
At entry into the ACROSTUDY, IGF-I values evaluated as fold-
ULN were similar in both groups (Table 1). During the follow-
up period, the percentages of patients with IGF-I within the
normal range continously increased in both groups, changing
from 52.2 to 59.5% in the Hypertension group and from 54.6 to
69.3% in the Normotension group, but were significantly higher
in the Normotension group when compared to the Hypertension
group 1–5 years after starting PEGV (p<0.001 (Figure 2).
Hypertensive patients received significantly higher PEGV doses
(p=0.014) for the first five years after the start of Somavert
therapy ranging from 15 to 18.3 mg/day, when compared to 13.5
to 16 mg/day in the Normotension group.
Mortality in the Hypertension Cohort
All adverse effects observed in ACROSTUDY are shown in Table
2. They were also previously reported for the overall population
by Buchfelder et al. (23). A total of 78 deaths (56% in males) were
observed: 68 in the Hypertension group (5.1%) and 10 in the
Normotension group (1.3%), and mortality rate was 13.2 per
1,000 patient years in the Hypertension group and 4 per 1,000
patient years in the Normotension group. The causes of death
were predominantly cardiovascular (31%), cerebrovascular
(18%), cancer (18%) and respiratory problems/sepsis (13%).
For further analysis, both cardiovascular and cerebrovascular
causes of death are classified as cardiovascular deaths, and
included cardiac arrest, ventricular fibrillation, myocardial
infarction, heart failure, aortic aneurysm rupture, cardiogenic
shock, bilateral massive pulmonary embolism, stroke/
cerebrovascular accident, basilar vein thrombosis and
subarachnoidal haemorrhage. The most common cause ofTABLE 1 | Differences in baseline characteristics, comorbidities and pituitary







Age at diagnosis of acromegaly
(years)
46.0 (13.1) 37.1 (12.4) <0.0001
Age at PEGV start (yrs) 53.9 (12.9) 44.0 (13.6) <0.0001






CV risk factors and comorbidities
Age at ACROSTUDY start (years) 55.6 (12.9) 45.6 (13.7) <0.0001
BMI (kg/m2) 30.5 (5.4) 28.3 (4.9) <0.0001
Smoking 27.7% 24.9% <0.0001
Cardiovascular disease 7.4% 2.5% <0.0001
Diabetes 20.2% 11.4% <0.0001
Hyperlipidemia 17.0% 5.6% <0.0001
Pituitary disease
Pituitary surgery 73.7% 82.7% <0.0001
Radiotherapy 30.9% 30.8% 0.9606
Pituitary deficiencies 53% 47% 0.0224
ACTH deficiency 24% 23% 0.7078
Baseline IGF-I (µg/L) 364 (283) 387 (278) 0.3265
IGF-I > ULN 88.9% 87.4% 0.3924
IGF-I (foldULN = IGF-I/ULN) 1.54 (1.11) 1.39 (0.87) 0.0841Data are shown as mean (SD) or percentage. CV, cardiovascular; CVD, cardiovascular
disease; IGF-I, insulin-like growth factor-I; PEGV, pegvisomant; ULN, upper limit of normal.A B
FIGURE 2 | Number and proportion of patients with normal IGF-I (bar charts) and respective PEGV (pegvisomant) dose (blue boxes) in the subcohorts of patients
with (A) and without (B) hypertension.November 2020 | Volume 11 | Article 577173
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Age of death ranged from 35.6 to 88.6 years (mean 68.4 years, SD
12.4). Two deaths occurred before the age of 40 and were caused
by ventricular fibrillation in one patient and aortic aneurysm
rupture in the other. Female patients died at an older age, with a
mean age at death of 71.8 years (SD 13.2) for females and 65.9
years (SD 11.3) for males. No gender differences were observed in
the distribution of causes of death.
For identifying which factors influenced the increased
mortality in the hypertension cohort we performed a
univariate analysis testing the relationship between mortality
and baseline factors obtained at the ACROSTUDY entry visit.
Older age, the concomitant presence of pituitary deficiencies,
diabetes, hyperlipidemia, and CVD were all significantly related
to mortality (Table 3). Gender, BMI, smoking habits and IGF-I
levels were not associated with mortality.
Using step-wise logistic regression analyses with all-cause-
mortality as the outcome measure, we found that only age at
diagnosis of acromegaly, the presence of CVD and pituitary
deficiencies independently predicted mortality (Table 3). In theFrontiers in Endocrinology | www.frontiersin.org 5Hypertension cohort, 34% of patients who died had already been
diagnosed with CVD at study entry. In the cohort of
hypertensive patients who survived, CVD was present in less
then 6%. Pituitary deficiency was present in 72% of hypertensive
patients who died, and in 51% of survivors. Traditional
cardiovascular risk factors such as smoking, BMI and gender
were not associated to mortality in acromegaly patients
with hypertension.
To further explore the importance of CVD and pituitary
deficiencies on mortality, we performed a Kaplan-Meyer analysis
testing the differences in survival curves between hypertensive
patients with and without pituitary deficiencies and CVD
(Figure 3). Survival in patients with acromegaly and
hypertension was not significantly influenced by concomitant
hypopituitarism (Figure 3A). The presence of CVD led to a
remarkable reduction in survival (Figure 3B).DISCUSSION
Previous studies have identified hypertension as an independent
factor related to an increased mortality in patients with
acromegaly (13, 26). Here we report the data from a large
international cohort study of patients with a long history of
acromegaly, necessitating long-term acromegaly-specific
therapies. We observed a high prevalence of hypertension,
which increases during the follow-up period, as patients get
older. In this cohort, the presence of hypertension is associated
with ageing and with a higher prevalence of diabetes,
hyperlipidemia and other cardiovascular risk factors. After five
years, blood pressure values decreased in the whole
ACROSTUDY cohort. In the subgroup of patients with
acromegaly and hypertension, the presence of CVD was the
most robust independent predictor of mortality in both logistic
regression and Kaplan-Meier analysis.
Improvements in glucose metabolism and blood pressure
observed after successful treatment interventions of acromegaly
with PEGV corroborate a direct link between GH-IGF-I excess
and hypertension and diabetes (6, 15, 24, 27, 28). Indeed, long-
term excess in GH/IGF-I plays an important role in the
development of hypertension, insulin resistance, diabetes and
obesity, which in turn also impact each other (8, 10, 15). As
PEGV is commonly used as a second- or third-line therapy in
acromegaly, most patients included in ACROSTUDY were either
not adequately controlled with other treatment modalities or
could not receive/tolerate other treatments. This may explain
why ACROSTUDY patients were older and had active disease
longer than other cohorts studied to date; this may also be the
reason that the ACROSTUDY population had a higher
prevalence of acromegaly-associated comorbidities at baseline
when compared to other cohorts (4, 22, 23). The long follow-up
period in the study extending to up to 12.2 years allowed us to
identify a large number of patients with hypertension, which
reached 1,344 patients (64% of the cohort) at the time of the
study data freeze for the second interim analysis. The high








Age at diagnosis of acromegaly
(years)
1.008 0.982 1.034 <0.0001
Age at ACROSTUDY start (yrs) 0.868 0.767 0.982 0.0247
Gender 0.797 0.487 1.304 0.3662
BMI 0.972 0.929 1.016 0.2105
Smoking 0.963 0.568 1.633 0.8895
Diabetes 0.558 0.342 0.910 0.0194
Hyperlipidemia 3.263 1.014 10.500 0.0474
Cardiovascular disease 0.124 0.071 0.215 <0.0001
IGF-I at study entry (µg/L) 1.001 0.999 1.002 0.3252
IGF-I at last visit (µg/L) 0.999 0.997 1.001 0.1997
Pituitary deficiencies 0.415 0.242 0.714 0.0015
ACTH deficiency 0.652 0.401 1.060 0.0844
Step-wise logistic regression analysis
Age at diagnosis of acromegaly
(years)
0.931 0.906 0.958 <0.0001
Cardiovascular disease 0.145 0.068 0.308 <0.0001






Subjects with AEs (all cause) 773 (57.5%) 364 (48.8%)
Subjects with treatment-related AEs 206 (15.3%) 131 (17.6%)
Serious adverse effects (SAEs)
Subjects with SAEs (all cause) 343 (25.5%) 116 (15.5%)
Subjects with treatment-related SAEs 35 (2.6%) 14 (1.9%)
Deaths (all non-treatment related) 68 (5.1%) 10 (1.3%)
Drugs withdrawn due to SAEs
Discontinued due to SAEs 116 (8.6%) 30 (4%)
Discontinued due to treatment-related SAEs 19 (1.4%) 5 (0.7%)Data are shown as total numbers and respective percentages. Treatment=Pegvisomant.November 2020 | Volume 11 | Article 577173
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its relationship to age, higher BMI, smoking and other
comorbidities, corroborates the multifactorial pathophysiology
of hypertension in patients with acromegaly, comparable to the
general population. To our knowledge, this is the largest cohort
of patients with acromegaly and hypertension studied to date.
Based on already published reports and our clinical
experience, hypertension in acromegaly is usually not very
severe, and can be effectively controlled with available
antihypertensive medications (6). This is also confirmed by our
observations on a small decrease in blood pressure values during
ACROSTUDY. Nevertheless, hypertension plays an important
pathophysiological role in the development of acromegaly-
associated comorbidities, such as insulin resistance, diabetes
and CVD (6, 8). Indeed, in the present study we found
significantly higher PEGV doses in patients with hypertension.
The main reasons for this might be the larger prevalence of
diabetes and the higher BMI in patients with hypertension and
acromegaly, when compared to patients without hypertension, as
the presence of diabetes necessitates higher PEGV doses for
achieving biochemical control (29). In terms of pituitary disease,Frontiers in Endocrinology | www.frontiersin.org 6the most significant difference was the fact that patients with
hypertension had undergone significantly less pituitary surgery.
Although the reason for this was not captured, it may be related
to the older age and multiple comorbidities found in the
hypertensive population and is in agreement with previous
reports on acromegaly in older patients (30).
At entry in ACROSTUDY the prevalence of CVD reported in
the sub-cohort of patients with acromegaly and hypertension
was 7.4%. Cardiac disease in acromegaly was found by other
investigators to depend on the amount and extent of GH
hypersecretion, and was often partly reversible after
normalization of GH levels via surgery or by blocking GH
action via PEGV (31). Hypertension plays an additive role,
aggravating GH/IGF-I-induced heart disease (5). A previous
study specifically analyzing all acromegaly patients for the
presence of CVD reported that all patients with hypertension
and diabetes had echocardiographic abnormalities (8). In clinical
practice, testing for the presence of CVD necessitates referrals to
other specialists and is not systematically done by the internist/
endocrinologist. Patients with acromegaly were found to have
morphological cardiac disease in the absence of signs andA
B
FIGURE 3 | Kaplan Meier plot survival curves in patients with acromegaly and hypertension in relation to the presence of (A) pituitary deficiencies and (B)
cardiovascular disease at baseline visit (ACROSTUDY entry).November 2020 | Volume 11 | Article 577173
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functional or morphological CVD might be underdiagnosed in
our population. Our data show that the prevalence of reported
CVD in the subcohort of patients with acromegaly and
normotension is not higher than in the general normotensive
population, while the prevalence of reported CVD in patients
with acromegaly and hypertension is similar to the general
population with well-treated hypertension (32). This evidence
supports the fact that arterial hypertension appears to be the
main factor contributing to the development of CVD in this
cohort of patients with acromegaly, who have a high frequency of
IGF-I normalization. In addition, our data are in line with recent
studies finding a lower frequency of CVD in acromegaly than
described in older cohorts, mainly attributed to better disease
control due to novel treatment modalities (10).
The current guidelines for diagnosing and treating
acromegaly promote screening all patients for the presence of
comorbidities, including CVD (20). Mortality in acromegaly has
improved during the last decades and is considered to be similar
to the normal population in well-controlled patients, and this is
linked to the lower prevalence of CVD (10, 18, 33). Here we show
that the presence of hypertension is associated with a 3.3 fold
increased mortality rate in patients with acromegaly,
nevertheless mortality rate in the cohort of patients with
acromegaly and hypertension appears similar to the mortality
rate of the general population with hypertension (34).
The strength of the present study is the prospective design for
capturing acromegaly comorbidities, and the inclusion of a large
number of patients with uncontrolled acromegaly, which led to a
high number of comorbidities and mortality events. Additional
strengths are the long-term follow up, the real-world setting with
inclusion of patients that may not have been enrolled in clinical
trials. Limitations include the retrospective classification of
Hypertension or Normotension groups, the investigator-based
definition of cardiovascular disease, the lack of information on
how adequately pituitary deficiencies were treated and the fact
that all patients were on PEGV, so there was no treatment
comparator group. Additional strengths/limitations of
ACROSTUDY overall were described in the previous
publication (23).
Taken together, here we report data on a very large cohort of
patients with acromegaly and hypertension, describing a higher
prevalence of other comorbidities and cardiovascular risk factors
and a 3.3 fold increased mortality when compared to patients
with acromegaly without hypertension. Our findings indicate
that hypertension significantly increases mortality in patients
with acromegaly, especially in the presence of concomitant CVD,
highlighting the importance of testing for and treating cardiac
disease in hypertensive patients with acromegaly.Frontiers in Endocrinology | www.frontiersin.org 7DATA AVAILABILITY STATEMENT
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